magnifying glass
logo for Arcutis Biotherapeutics

Arcutis Biotherapeutics

Get Full Access

Who is Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis' dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions, with one NDA under review with the FDA and three Phase 3 clinical data readouts anticipated by the end of 2022. The company's lead program, topical roflumilast, has the potential to advance the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.Read More

Headquarters

Headquarters:

3027 Townsgate Rd, Ste 300, Westlake Village, California, 91361, United States
Phone Number

Phone Number:

(805) 418-5006
Employees

Employees:

147
Revenue

Revenue:

$31 Million
Stock Symbol

Stock Symbol:

ARQT
Arcutis Biotherapeutics's Social Media
SIC Code 28,283
NAICS Code 541,32541
Ticker NASDAQ: ARQT
Popular Searches:

Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics , Inc.

Arcutis Biotherapeutics

Arcutis , Inc.

Arcutis Biotherapeutics Inc

Top Competitors of Arcutis Biotherapeutics

Employess
<25
revenue
<$5 Million

1

Employess
393
revenue
$132 Million

2

Employess
<25
revenue
<$5 Million

3

Employess
75
revenue
<$5 Million

4

Employess
25
revenue
<$5 Million

5

Employess
200
revenue
$24 Million

6

Arcutis Biotherapeutics's Org Chart

Frank Watanabe
Frank Watanabe

Chief Executive Officer & President

PhonePhoneEmailEmail
Scott Burrows
Scott Burrows

Chief Financial Officer

PhonePhoneEmailEmail
Keith Klein
Keith Klein

General Counsel

PhonePhoneEmailEmail

PhonePhoneEmailEmail
Illustration of an envelope

Arcutis Biotherapeutics Company Metrics

Company Insights
Employee Growth Rate
Funding
Funding DateRoundAmountInvestors

Dec 23, 2021

Debt

$225M

SLR Capital Partners, LLC

Oct 21, 2019

Series C

$94M

HBM Healthcare Investments

Sep 01, 2018

Series B

$58M

OrbiMed

See More

$391M

Total Funding Amount

$225M

Most Recent Funding Amount

4

Number of Funding Rounds

Revenue
QuarterRevenue

'21 - Q1

18229000

'21 - Q2

18229000

Arcutis Biotherapeutics's Tech Stack

Google Global Site Tag

By

Google

Office 365

By

Microsoft

WordPress.org

By

Automattic
See more technologies

Arcutis Biotherapeutics News & Media

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 135,900 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 324,200 shares of Arcutis’ common stock to 49 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Boa

Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis

WESTLAKE VILLAGE, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the enrollment of the last subject in its ARRECTOR pivotal Phase 3 trial of topical roflumilast foam in adolescents and adults with scalp and body psoriasis. Roflumilast foam is a once-daily, topical formulation of a highly potent and selective phosphodiesterase-4 (PDE4

Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts

WESTLAKE VILLAGE, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, outlines the company’s growth strategy and continued clinical progress of its broad immuno-dermatology pipeline during today’s Investor Day in Boston, MA at 10:30 a.m. EST.
Subscribe to "Arcutis Biotherapeutics" News

Frequently Asked Questions regarding Arcutis Biotherapeutics

Where are Arcutis Biotherapeutics’s headquarters?

Arcutis Biotherapeutics’s headquarters are in 3027 Townsgate Rd, Ste 300, Westlake Village, California, 91361, United States

What is Arcutis Biotherapeutics’s phone number?

Arcutis Biotherapeutics’s phone number is (805) 418-5006

What is Arcutis Biotherapeutics’s stock symbol?

Arcutis Biotherapeutics’s stock symbol is ARQT

What is Arcutis Biotherapeutics’s official website?

Arcutis Biotherapeutics’s official website is www.arcutis.com

What is Arcutis Biotherapeutics’s Revenue?

Arcutis Biotherapeutics’s revenue is $31 Million

What is Arcutis Biotherapeutics’s SIC code?

Arcutis Biotherapeutics’s SIC: 28,283

What is Arcutis Biotherapeutics’s NAICS code?

Arcutis Biotherapeutics’s NAICS: 541,32541

How many employees are working in Arcutis Biotherapeutics?

Arcutis Biotherapeutics has 147 employees

What is Arcutis Biotherapeutics’s industry?

Arcutis Biotherapeutics is in the industry of: Drug Manufacturing & Research, Pharmaceuticals, Healthcare

Who are Arcutis Biotherapeutics’s main competitors?

Arcutis Biotherapeutics's main competitors are: Verrica Pharmaceuticals, Atara Bio, Curemark, Aclaris Therapeutics

What is Arcutis Biotherapeutics's tech stack?

The technologies that are used by Arcutis Biotherapeutics are: Google Global Site Tag, Pantheon, Office 365, WordPress.org

Who is Arcutis Biotherapeutics's CEO?

Arcutis Biotherapeutics's CEO is Frank Watanabe

Who is Arcutis Biotherapeutics's CFO?

Arcutis Biotherapeutics's CFO is Scott Burrows

See more information about Arcutis Biotherapeutics
4.4/5 on G2 Crowd